Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inmune Bio (INMB) Other Non-Current Assets (2021 - 2025)

Inmune Bio (INMB) has disclosed Other Non-Current Assets for 5 consecutive years, with $595000.0 as the latest value for Q4 2025.

  • Quarterly Other Non-Current Assets rose 653.16% to $595000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $595000.0 through Dec 2025, up 653.16% year-over-year, with the annual reading at $595000.0 for FY2025, 653.16% up from the prior year.
  • Other Non-Current Assets hit $595000.0 in Q4 2025 for Inmune Bio, down from $746000.0 in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $746000.0 in Q3 2025 to a low of $49000.0 in Q1 2025.
  • Historically, Other Non-Current Assets has averaged $188388.9 across 5 years, with a median of $99000.0 in 2021.
  • Biggest YoY gain for Other Non-Current Assets was 809.76% in 2025; the steepest drop was 53.77% in 2025.
  • Year by year, Other Non-Current Assets stood at $99000.0 in 2021, then changed by 0.0% to $99000.0 in 2022, then skyrocketed by 32.32% to $131000.0 in 2023, then tumbled by 39.69% to $79000.0 in 2024, then surged by 653.16% to $595000.0 in 2025.
  • Business Quant data shows Other Non-Current Assets for INMB at $595000.0 in Q4 2025, $746000.0 in Q3 2025, and $570000.0 in Q2 2025.